0001209191-19-020633.txt : 20190320 0001209191-19-020633.hdr.sgml : 20190320 20190320174929 ACCESSION NUMBER: 0001209191-19-020633 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170802 FILED AS OF DATE: 20190320 DATE AS OF CHANGE: 20190320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flynn Daniel Lee CENTRAL INDEX KEY: 0001713712 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 19695448 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC STREET 2: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-08-02 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001713712 Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 500 TOTTEN POND ROAD WALTHAM MA 02451 0 1 0 0 Chief Scientific Officer Common Stock 2017-08-02 5 G 0 E 55270 0.00 D 0 I See Footnote Common Stock 2017-08-02 5 G 0 E 55270 0.00 A 147049 I See Footnote This transaction involved the transfer of the Reporting Person's interest in Biochenomix, LLC to the Daniel L. Flynn Irrevocable Trust. The Reporting Person's daughter is trustee of the trust and the Reporting Person's spouse is the sole lifetime beneficiary of the trust. Biochenomix, LLC holds 55,270 shares directly and the Daniel L. Flynn Irrevocable Trust holds 91,779 shares directly. The Reporting Person disclaims Section 16 beneficial ownership over all such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that the Reporting Person has beneficial ownership of such shares for Section 16 or for any other purposes. /s/ Jeffrey M. Held, Attorney-in-Fact 2019-03-20